Blog
Kinetics of lentiviral vector transduction in human CD34+ cells Human hematopoietic stem cells (HSCs) are refractory to the lentiviral vector transduction. Improvement of transduction efficiency for human HSCs remains crucial for further development of gene therapy especially for non-immunodeficiency diseases. In this report, the authors investigated which step(s) could be…
Development of 3rd Generation Cocal Envelope Producer Cell Lines for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T Cells Lentiviral vectors (LVs) are currently considered the gold standard for hematopoietic stem cell (HSC) gene therapy and for immunotherapies with genetically modified T cells. LVs have commonly been pseudotyped…
Lentivirus pre-packed with Cas9 protein for safer gene editing The CRISPR/Cas9 system has democratized genome editing and opens the door to an unprecedented use of genome editors. This powerful method is allowing researchers to ask questions that were previously unaskable, leading to new insights into the basis of fundamental biological…
Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles RNA delivery is an attractive strategy to achieve transient gene expression in research projects and in cell- or gene-based therapies. However, RNA transfer tools developed until that are not enough efficient to be…
DECKO: Single-oligo, dual-CRISPR deletion of genomic elements including long non-coding RNAs Recently, Estel Aparicio-Prat et al. published a study about a new genome editing system based on CRISPR and lentiviral vector technologies, this tool was specifically designed to knockout long non-coding RNAs. They spell this new system DECKO for Double…